Epigenetic markers of esophageal cancer: DNA methylation

   


1. Rostov Cancer Research Institute, Rostov-on-Don, Russia
Type: Review
DOI: 10.18097/PBMC20166205520      UDK: 616.329-577.2      PubMed Id: 27797326
Year: 2016 vol: 62  issue:5  pages: 520-526
Abstract: Adenocarcinoma and squamous cell carcinoma are the most common types of esophageal cancer with a constant tendency to increase the incidence of growth on the background of the high mortality, which makes particularly the development of new biomarkers that complement and improve the early diagnosis of this disease. Despite the impressive number of studies in routine clinical practice is used only marker of esophageal cancer – ERBB2/HER2 status. This review summarizes data on the identified epigenetic markers of the aberrant methylation of the genome, which may be useful for early detection of esophageal cancer, prognosis estimation and / or prediction of response to treatment. The development of new high-tech genome-wide screening, such as beadarray and immunoprecipitation sequencing method used for the wideband genotyping, but for the analysis of transcriptome and metilom, provides a comprehensive picture of genetic and epigenetic changes during tumorigenesis. Note the need to verify the most biomarkers on large representative samples for the development of valid diagnostic panels, suitable for large-scale screening of risk groups.
Download PDF:
Reference: Kit O.I., Vodolazhskiy D.I., Kolesnikov E.N., Timoshkina N.N., Epigenetic markers of esophageal cancer: DNA methylation, Biomeditsinskaya khimiya, 2016, vol: 62(5), 520-526.
This paper is also available as the English translation:10.1134/S1990750817010048
References
 2017(Vol:63)
 2016(Vol:62)
 2015(Vol:61)
 2014(Vol:60)
 2013(Vol:59)
 2012(Vol:58)
 2011(Vol:57)
 2010(Vol:56)
 2009(Vol:55)
 2008(Vol:54)
 2007(Vol:53)
 2006(Vol:52)
 2005(Vol:51)
 2004(Vol:50)
 2003(Vol:49)